The global parathyroid disorders market size is anticipated to expand at a significant rate during the forecast period, between 2021 and 2028. Growing improvement in the regulatory framework and favorable reimbursement policies imposed by the government to support the healthcare industry are driving the market.
Parathyroid glands produce and secrete a parathyroid hormone that regulates and maintains calcium and phosphorus metabolism in the body. Parathyroid disease affects the parathyroid, located in the neck near to the thyroid. Parathyroid disorders are caused when the abnormal level of calcium in the blood causes brittle bones, kidney stones, weakness, fatigue lump in the neck, difficulty in swallowing and speaking, and other problems. There are three types of parathyroid disease: hyperparathyroidism, parathyroid cancer, and hypoparathyroidism. However, parathyroid disorder can be treated by monitoring, medication, surgery, and dietary supplements.
Market Trends, Drivers, Restraints, and Opportunities:
- Growing geriatric population and rising incidence of parathyroid disorder worldwide are driving the global parathyroid disorders market.
- Increasing expenditure and developing medical and healthcare infrastructure is boosting the parathyroid disorder market.
- Growing adoption of advanced technologies that help in the early diagnosis of parathyroid disorder is fueling the market.
- The availability of counterfeit and misbranded drugs and patent expiration of some existing drugs is hindering the market.
- Lack of technical knowledge related to parathyroid disorders and side-effects of treatment on patient’s health is hampering the market.
- Increasing funding on research to develop new techniques and drugs that help in treating the parathyroid disorder is generating opportunities in the market.
- The growth in prevalence of osteoporosis and an increasing accident leads to an increased risk of fracture are creating opportunities in the market.
Scope of the report:
The report on the global parathyroid disorders market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
| Attributes | Details |
| Report Title | Parathyroid Disorders Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018 & 2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Types (Hyperparathyroidism (HPT) [Primary, Secondary and Tertiary], Parathyroid Cancer, and Hypoparathyroidism), Diagnosis (Blood tests, Imaging tests [CT or CAT (Computed Axial Tomography) scans, MRI (Magnetic Resonance Imaging) scans, X-ray, Ultrasound, Bone Density test, and Sestamibi scan], and Urine tests), Treatments (Surgery, Radiation Therapy, Drugs [Calcimimetics, Hormone Replacement Therapy, and Bisphosphonates]), and Others, End-users (Hospitals & Clinics, Diagnostic Centers, Drug Stores, Pharmacies, and Others) |
| Regional Scope | Asia Pacific, North America, Europe, Latin America, and Middle East & Africa |
| Report Coverage | Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast |
| Key Players Covered | Amgen Inc, Bayer AG, BD, F. Hoffmann-La Roche Ltd, Genentech, Inc, Lilly, Medtronic, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd |
Parathyroid Disorders Market Segment Insights:
HyThe hyperparathyroidismegment held substantial market share in 2020
In terms of types, the global parathyroid disorders market is segmented into hyperparathyroidism (HPT), parathyroid cancer, and hypoparathyroidism. The hyperparathyroidism (HPT) segment is further sub-segmented into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism. The hyperparathyroidism (HPT) segment constituted a significant market share in 2020 and is projected to grow in the forecast period. Hyperparathyroidism is a serious disease that becomes very destructive with time and can lead to several problems including osteoporosis, kidney failure, stroke, and cardiac arrhythmias throughout the body. Moreover, hyperparathyroidism (HPT) is mostly diagnosed between the ages of 50 and 60, and women are affected three times as often as men, which are anticipated to propel the segment during the forecast period.
Blood segment to hold significant market share
On the basis of diagnosis, the global parathyroid disorders market is segregated into blood tests, imaging tests, and urine tests. The imaging tests segment is further sub-segmented into CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, X-ray, ultrasound, bone density test, and sestamibi scan. The blood tests segment constituted a significant market share in 2020 and is expected to hold a significant share of the market during the forecast period. The blood test diagnosis is used to measure the level of parathyroid hormone in the blood. Moreover, blood test helps the surgeon to know whether patient’s body is making too much or too little parathyroid hormone. These factors are anticipated to propel the segment during the forecast period.
Surgery segment to grow at a significant pace in the near future
Based on treatments, the parathyroid disorders market is segregated into surgery, radiation therapy, drugs, and others. The drugs segment is further sub-segmented into calcimimetics, hormone replacement therapy, and bisphosphonates. The surgery segment is expected to hold a significant share of the market during the forecast period, attributed to the most effective option to treat the disease. It involves removing overactive parathyroid glands i.e. removing cancer in an operation. Moreover, surgery can be performed either in a minimally invasive way or by a standard neck exploration, which is expected to boost the segment during the forecast period.
Hospitals segment to grow during the forecast period
In terms of end-users, the global parathyroid disorders market is segregated into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others. The hospital segment is expected to hold a significant share of the market during the forecast period, due to the growing need for advanced healthcare infrastructures for treating parathyroid disorder. Moreover, surgical treatment is highly adopted for treating the parathyroid disorders. Surgeries can effectively perform in the hospital associated with the growing number of hospitals equipped with advanced infrastructure. Additionally, hospitals provide adequate facilities to the patients. The factors are anticipated to support the segment during the forecast period.
North America dominates the global market
On the basis of regions, the global parathyroid disorders market is split into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America constituted a significant share of the market in 2020, attributed to the presence of major key players such as Amgen Inc, BD, Genentech, Inc, and Medtronic. The market in North America is projected to expand at a significant CAGR during the forecast period, due to the rising occurrence of parathyroid disorders. Moreover, increasing investments and expenditure to develop the healthcare industry and growing research and development studies on parathyroid disorders are propelling the market in North America.
Segments
By Types
- Hyperparathyroidism (HPT)
- Primary
- Secondary
- Tertiary
- Parathyroid Cancer
- Hypoparathyroidism
By Diagnosis
- Blood tests
- Imaging tests
- CT or CAT (Computed Axial Tomography) scans
- MRI (Magnetic Resonance Imaging) scans
- X-ray
- Ultrasound
- Bone Density test
- Sestamibi scan
- Urine tests
By Treatments
- Surgery
- Radiation Therapy
- Drugs
- Calcimimetics
- Hormone Replacement Therapy
- Bisphosphonates
- Others
By End-users
- Hospitals & Clinics
- Diagnostic Centers
- Drug Stores
- Pharmacies
- Others
By Regions
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
By Key Players
- Amgen Inc
- Bayer AG
- BD
- F. Hoffmann-La Roche Ltd
- Genentech, Inc
- Lilly
- Medtronic
- Novartis Pharmaceuticals Corporation
- Novo Nordisk A/S
- Teva Pharmaceutical Industries Ltd
Competitive Landscape
Key players in the global parathyroid disorders market include Amgen Inc, Bayer AG, BD, F. Hoffmann-La Roche Ltd, Genentech, Inc, Lilly, Medtronic, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd. These players engage in mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence.
Request For Customization
Enquiry Before Buying
Speak With Analyst
